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Background. Substance use is common among people living with human immunodeficiency virus (PLWH) and a barrier to 
achieving viral suppression. Among PLWH who report illicit drug use, we evaluated associations between HIV viral load (VL) and 
reduced use of illicit opioids, methamphetamine/crystal, cocaine/crack, and marijuana, regardless of whether or not abstinence was 
achieved.
Methods. This was a longitudinal cohort study of PLWH from 7 HIV clinics or 4 clinical studies. We used joint longitudinal and 
survival models to examine the impact of decreasing drug use and of abstinence for each drug on viral suppression. We repeated 
analyses using linear mixed models to examine associations between change in frequency of drug use and VL.
Results. The number of PLWH who were using each drug at baseline ranged from n = 568 (illicit opioids) to n = 4272 (mari-
juana). Abstinence was associated with higher odds of viral suppression (odds ratio [OR], 1.4–2.2) and lower relative VL (ranging 
from 21% to 42% by drug) for all 4 drug categories. Reducing frequency of illicit opioid or methamphetamine/crystal use without 
abstinence was associated with VL suppression (OR, 2.2, 1.6, respectively). Reducing frequency of illicit opioid or methampheta-
mine/crystal use without abstinence was associated with lower relative VL (47%, 38%, respectively).
Conclusions. Abstinence was associated with viral suppression. In addition, reducing use of illicit opioids or methampheta-
mine/crystal, even without abstinence, was also associated with viral suppression. Our findings highlight the impact of reducing 
substance use, even when abstinence is not achieved, and the potential benefits of medications, behavioral interventions, and harm-
reduction interventions.
Keywords. substance use; drug use; heroin; viral suppression; abstinence.
There are approximately 1.1 million people living with human 
immunodeficiency virus (PLWH) in the United States, and sub-
stance use rates are high [1–3]. An early study found that ap-
proximately 40% of PLWH reported illicit drug use in the prior 
year [2]. A more recent study found that rates varied by drug, 
with current use (3 months) ranging from 2% (illicit heroin) to 
24% (marijuana) [4]. Illegal and legal (eg, alcohol) substance 
use is associated with detrimental health outcomes, acting as a 
barrier to the HIV care continuum, including poor engagement 
in care [5], a lower likelihood of receiving antiretroviral therapy 
(ART) [6], decreased ART adherence [7–9], and increased mor-
tality [10]. Substance use disorders have been associated with 
poor viral suppression rates [7–9, 11] and, thus, morbidity, 
mortality, and potential HIV transmission [12, 13].
The inverse association between substance use and HIV viral 
load (VL) has been noted in several studies. However, studies 
have often examined only 1 drug such as stimulants [7] or 
opioids [14] or examined injection drug use [9, 11]. Studies 
have typically not evaluated the independent contributions of 
each substance used by PLWH let alone the frequency of use 
by drug. This is an important gap given differences in impact of 
individual substances on outcomes such as adherence and de-
pression among PLWH [4, 15–17].
Furthermore, many substance use and HIV treatment out-
come studies have been cross-sectional or only focused on 
baseline substance use [4, 5, 9], limiting the ability to eval-
uate longitudinal associations, particularly among those 
whose substance use severity changes over time. Substance 
use interventions often lead to a reduction in frequency of use 
even if abstinence is not achieved [18, 19]; however, the impact 
of reduced substance use frequency on VL has not been well 
studied.
Our purpose in this study was to examine relationships be-
tween changes in drug use over time and VL. We examined the 
associations of reduced use of illicit opioids, methamphetamine/
crystal, cocaine/crack, and marijuana, regardless of whether 
those reductions resulted in abstinence. We hypothesized that 
successful reduction in drug use frequency even if abstinence 
was not achieved, would have beneficial effects on VL. We 
hypothesized this effect would vary by type of drug.
METHODS
Study Population
This study was conducted among PLWH from the Centers for 
AIDS Research Network of Integrated Clinical Sites (CNICS) 
cohort. CNICS is a longitudinal, observational study of PLWH 
who received primary care at CNICS sites from 1 January 
1995 to the present [20]. We conducted additional analyses 
adding PLWH from the Criminal Justice Seek, Test, Treat, and 
Retain (STTR) collaboration to maximize diversity. STTR was 
initiated by the National Institute on Drug Abuse and combines 
data from observational studies and trials intended to improve 
outcomes along the HIV care continuum for people involved in 
the criminal justice system, many of whom have substance use 
disorders [21, 22]. Four STTR studies were included to enhance 
demographic, clinical, and geographic diversity.
Study Participants
These analyses included PLWH aged ≥18 years who completed 
longitudinal assessments of substance use frequency, including 
illicit opioids, methamphetamines/crystal, cocaine/crack, and 
marijuana. Only individuals who used 1 of the drugs of interest 
at baseline were included in analyses for that particular drug. 
Participants had to have 2 or more VL measurements taken 
after 2010 to be eligible. CNICS participants were PLWH who 
received clinical care at 1 of 7 participating sites to ensure geo-
graphic and racial/ethnic diversity. The STTR studies were STT-
COIP: an Illinois study targeting PLWH leaving jail or prison 
[23]; STRIDE2: a study of opioid users with HIV around the 
District of Columbia [24]; CARE+RCT: a study of PLWH in jail 
or recently released from jail around the District of Columbia 
metropolitan area [25]; and VISTA, a Vietnam-based study of 
male PLWH who injected drugs [26].
Data Sources
Both CNICS and STTR have data repositories that harmonize 
and integrate demographic, clinical, laboratory, and other data 
such as patient-reported substance use assessments [20, 22].
Drug and Alcohol Use
PLWH complete a 10–12 minute clinical assessment with 
touch-screen tablets approximately every 6 months as part of 
routine care in CNICS [27, 28]. The CNICS clinical assessment 
includes measures of drug use (modified Alcohol, Smoking, 
and Substance Involvement Screening Test [ASSIST]) [29, 
30], alcohol use (Alcohol Use Disorders Identification Test 
[AUDIT-C] [31, 32]), and other domains. While the approach 
and drug use instruments varied for STTR studies, each one 
had instruments with similar items (eg, How many times did 
you use marijuana during the last 30 days?). Follow-up assess-
ment timing varied; however, all studies assessed substance use 
longitudinally.
For these analyses, we focused on drug use frequency. 
Drugs of interest included heroin and other illicit opioids in-
cluding prescription opioids not taken as prescribed, metham-
phetamine/crystal including noncocaine stimulants, cocaine/
crack, and marijuana. We defined drug use frequency among 
those using a drug at baseline as the number of days during 
the last 30 days that a drug was used. We also categorized fre-
quency of use as less than weekly, 1–3 times per week, and 
daily/almost daily to enhance ease of interpretation of figures. 
To analyze the impact of changes in drug use, we categorized 
each drug at follow-up assessments as abstinence (no use in 
the prior 30 days for an individual who used that drug at base-
line), reduction without abstinence (the number of days used 
in the prior 30 days was fewer than number of days used at 
baseline [18]), and nondecreasing (the number of days used 
in the prior 30 days was the same or greater than baseline). In 
addition, we explored polydrug use, defined as currently using 
drugs from 2 or more of the 4 categories (ie, heroin and other 
illicit opioids, methamphetamine/crystal, cocaine/crack, and 
marijuana).
Outcome
The primary outcome of interest was viral suppression, defined 
as an undetectable VL (≤400 copies/mL). We also evaluated 
VL (copies/mL) at each time point, which was log transformed 
(base10) due to skew (log10VL). We then back-transformed VL 
coefficients by raising them to the power of 10. We calculated 
relative VL values, which were defined as the ratio of VL of 
PLWH with abstinence or reduction for each drug divided by 
the VL of PLWH who had nondecreasing drug use.
Statistical Models
We calculated descriptive statistics including mean, median, 
frequency, and standard deviation.
We conducted analyses using joint longitudinal and survival 
models [33] to examine the impact of decreasing drug use and 
abstinence on viral suppression using a separate model for each 
drug category (heroin and other illicit opioids, methamphet-
amine/crystal, cocaine/crack, and marijuana) due to known 
limitations with less complex models [34]. These models were 
limited to CNICS as they have convergence issues in small 
datasets [35]. We censored individuals who died, dropped out 
of clinical care, or did not have VL measured for 18 months.
We also conducted sensitivity analyses using separate linear 
mixed models for each drug category and for each study (CNICS 
and each STTR study) to examine the impact of decreasing 
drug use and abstinence on VL over time. We used linear mixed 
models since they inherently handle unbalanced numbers and 
times of observations between individuals and clustering by 
participant [36].
For both types of models, PLWH reporting current use of a 
given drug at the first time point were included in the model 
for that drug. We modeled change in drug use frequency as 
a time-updated categorical variable: abstinence, reduction 
without abstinence, or nondecreasing frequency of drug use 
compared to baseline. Models were adjusted for age, sex, cohort 
entry year, and follow-up time, although there were exceptions. 
For example, VISTA participants were all male; therefore, these 
models did not adjust for sex. Due to differences in how models 
handle time, the linear mixed models adjusted for calendar time 
not entry and follow-up time. All models adjusted for concom-
itant frequency of other drugs and frequency of any alcohol 
use and binge alcohol use in a 30-day period. We did not ad-
just for ART use or adherence as these are potentially mediators 
on the pathway between substance use and VL. Studies with 
<15 participants using a given drug at baseline were excluded 
from that analysis. Substance use assessments taken while 
incarcerated were excluded as baseline values.
Due to heterogeneity across studies, we calculated pooled 
estimates via traditional fixed-effects meta-analysis statistical 
models [37] for both decreasing use and abstinence for each 
drug. Fixed-effects meta-analysis modeling was used because 
the individual studies can be regarded as mutually independent 
[38]. This allowed us to include heterogeneous studies such as 
VISTA, which is set in an international context, without losing 
internal validity of estimates. This approach allows impact to be 
measured taking into account a much larger and more diverse 
population. We also repeated analyses without the VISTA study.
Finally, we used joint longitudinal and survival models to ex-
amine the impact of switching from polydrug use to single or 
no drug use on viral suppression over time. This analysis was 
conducted with CNICS only due to insufficient numbers of 
polydrug users in the other studies. These models were adjusted 
for age, sex, cohort entry year, follow-up time, frequency of al-
cohol use, and frequency of binge alcohol use.
RESULTS
Baseline demographic and clinical characteristics of 12  492 
PLWH in CNICS are listed in Table 1 overall and by baseline 
drug use. The mean age was 44, and 47% were white. Marijuana 
was the most widely used drug at baseline followed by meth-
amphetamine/crystal. Mean follow-up was 3.9 years (standard 
deviation, 2.6), and mean number of VL values were 10.
Drug use frequency in the last 30 days among those in CNICS 
using each drug at baseline is shown in Figure 1, with illicit 
opioids and marijuana having the largest percentage of daily or 
almost daily users. Changes in use over time from baseline to 
the most recent assessment are shown in Figure 2. Marijuana 
users had the lowest percentage achieving abstinence and the 
highest percentage with nondecreasing frequency.
Overall, among users of the 4 drug classes with baseline de-
tectable VL, the proportions by drug class who achieved viral 
suppression were higher among those who reduced (56%–72%) 
or quit (68–73%) vs those who did not decrease (41%–54%) 
drug use for all 4 drug classes.
We examined the likelihood of viral suppression (binary out-
come) among 12 492 PLWH in the CNICS cohort using joint 
longitudinal and survival models. Abstinence was associated 
with viral suppression for all 4 groups of drugs (Figure 3) with 
odds ratios (ORs) ranging from 1.42 (95% confidence interval 
[CI], 1.24–1.63) for PLWH who became abstinent from mari-
juana up to 2.18 (95% CI, 1.56–3.04) for PLWH who became 
abstinent from illicit opioids. For people who reduced use 
without abstinence, reducing the frequency of methampheta-
mine/crystal use (OR, 1.65; 95% CI, 1.25–2.16) and reducing 
the frequency of illicit opioids (OR, 2.72; 95% CI, 1.47–5.04) 
were associated with VL suppression (Figure 3; survival model 
component, Supplementary Table 3).
We conducted sensitivity analyses to examine rela-
tive VL among CNICS and STTR studies. Supplementary 
Table 1 describes demographic and clinical characteristics 
of participants in CNICS and STTR studies. The number 
of participants per study varied from 82 to 12  492 PLWH. 
As described above, we limited analyses to studies with ≥15 
individuals using a particular drug at baseline to be included in 
analyses for that drug. Four studies were used for illicit opioids 
and marijuana; fewer studies were used for the other drugs 
(Supplementary Table 2). The number of individuals included 
who were using each drug at baseline ranged from n = 568 (il-
licit opioids) to n = 4272 (marijuana).
Abstinence was associated with lower VL in pooled analyses 
for all 4 drug classes (Figure 4). Abstinence from illicit opioid 
use was associated with a log10VL difference of –0.218 (P < .001), 
resulting in a relative VL of 0.61 or 39% lower VL compared to 
those who continued illicit opioid use without decreasing fre-
quency. Abstinence from methamphetamine/crystal was asso-
ciated with a log10VL difference of –0.239 (P  <  .001), resulting 
in a relative VL of 0.58 or 42% lower VL. Abstinence from co-
caine/crack was associated with a log10VL difference of –0.160 
(P  <  .001), resulting in a relative VL of 0.69 or 31% lower VL 
compared to those who continued cocaine/crack use. Abstinence 
from marijuana among those using marijuana at baseline was as-
sociated with a log10VL difference of –0.105 (P < .001), resulting 
in a relative VL of 0.79 or 21% lower VL compared to those who 
continued marijuana use without decreasing frequency.
 We also examined the impact of reducing use frequency 
of all 4 drugs without abstinence (Figure 4). Reducing use 
without abstinence for cocaine/crack and marijuana was 
not associated with significant VL differences. Reducing 
use without abstinence of illicit opioids and methampheta-
mine/crystal was associated with significantly lower VL. In 
the pooled analyses, decreasing methamphetamine/crystal 
use without abstinence was associated with a log10VL differ-
ence of –0.159 (P  =  .005), resulting in a relative VL of 0.69 
or 31% lower VL compared to those who did not reduce use. 
Decreasing illicit opioid use without abstinence was associ-
ated with a log10VL difference of –0.366 (P < .001), resulting in 
a relative VL of 0.43 or 57% lower VL. Repeating relative VL 
analyses excluding the VISTA study or limited to CNICS only 
yielded similar results.
We examined change in polydrug use among 1445 
participants who were using 2 or more drugs at baseline. 
Changing from polysubstance use to no drug use was associated 
with an increased odds of viral suppression (OR, 2.33; 95% CI, 
Table 1. Baseline Demographic and Clinical Characteristics of People Living With Human Immunodeficiency Virus at the Centers for AIDS Research 
Network of Integrated Clinical Systems Sites Across the United States by Baseline Substance Use
Characteristic





N (%)a N (%)a N (%)a N (%)a N (%)a
N 12 492 403 1329 1072 4167
Age mean (SD), y 44 (11) 43 (10) 41 (10) 44 (10) 42 (11)
Female 1979 (16) 66 (16) 61 (5) 218 (20) 407 (10)
Race/Ethnicity
 White 5875 (47) 200 (50) 833 (63) 367 (34) 2185 (52)
 Black 4110 (33) 143 (35) 172 (13) 506 (47) 1231 (30)
 Hispanic 1881 (15) 44 (11) 244 (18) 140 (13) 536 (13)
 Other 626 (5) 16 (4) 80 (6) 59 (6) 215 (5)
Current use
Heroin/other illicit opioids 403 (3) 403 (100) 159 (12) 144 (13) 242 (6)
 Methamphetamine/crystal 1329 (11) 159 (39) 1329 (100) 295 (28) 800 (19)
 Cocaine/crack 1072 (9) 144 (36) 295 (22) 1072 (100) 634 (15)
 Marijuana 4167 (33) 242 (60) 800 (60) 634 (59) 4167 (100)
Frequency of drug use (in prior 30 days) among those with  
current use, mean number of days (SD)
Heroin/other illicit opioids 7 (12) 7 (12) 6 (11) 8 (12) 7 (12)
 Methamphetamine/crystal 6 (11) 9 (13) 6 (11) 5 (10) 6 (10)
 Cocaine/crack 3 (8) 6 (11) 3 (8) 3 (8) 3 (7)
 Marijuana 12 (14) 14 (14) 10 (13) 11 (13) 12 (14)
Current alcohol use (any use) 8330 (67) 290 (72) 964 (73) 872 (81) 3368 (81)
Frequency of alcohol use among those currently drinking
Days of use out of 30 days, mean (SD) 5 (6) 7 (7) 5 (6) 7 (7) 6 (7)
Binge alcohol use 4367 (35) 181 (45) 559 (42) 622 (58) 2034 (49)
Frequency of binge alcohol use among those with binge drinking
Days of binge use out of 30 days, mean (SD) 2 (6) 5 (9) 3 (7) 4 (8) 2 (6)
Number of substances used
 0 7350 (59) 0 0 0 0
 1 3698 (30) 94 (23) 419 (32) 319 (30) 2866 (69)
 ≥2 1444 (12) 309 (77) 910 (68) 753 (70) 1301 (31)
Viral load, copies/mL UD UD UD UD UD
Median (IQR) (UD–UD) (UD–961) (UD–4627) (UD–1244) (UD–UD)
CD4 count cells/mm3 506 480 495 479 521
Median (IQR) (320–709) (281–707) (311–697) (289–689) (333–726)
Abbreviations: IQR, interquartile range; SD, standard deviation; UD, undetectable.
aUnless otherwise specified.
1.80–3.01) as was reducing from polydrug use to a single drug 
(OR, 1.60; 95% CI, 1.32–1.93).
DISCUSSION
In this study, we examined associations between reducing drug 
use frequency and drug abstinence with viral suppression and 
VL changes over time. It included PLWH from 7 CNICS clinics 
and 4 STTR studies to ensure geographic and clinical diversity. 
Abstinence from illicit opioids, methamphetamines/crystal, 
cocaine/crack, and marijuana among baselines users was as-
sociated with higher odds of viral suppression and lower VL. 
Reducing frequency without abstinence for illicit opioids or 
methamphetamines/crystal was associated with higher odds of 
viral suppression and significantly lower VL over time.
The results demonstrate a positive association between absti-
nence and higher likelihood of viral suppression or lower rel-
ative VL, consistent with prior studies. Marijuana abstinence 
was associated with the smallest reduction in VL and odds of 
viral suppression, while abstinence from illicit opioids and co-
caine/crystal was associated with the largest. One prior study 
found that current injection drug users (IDU) were less likely 
to achieve VL suppression than former or non-IDU, although 
changes in use over time were not examined [9]. Mimiaga et al 
found that current drug use (excluding marijuana) was as-
sociated with poorer ART adherence [4]. Chitsaz et  al found 
that current drug use and severity of use were negatively asso-
ciated with receiving and adhering to ART [5]. Springer et al 
found that treating opioid use disorder with extended-release 
naltrexone led to more viral suppression after release among 
prisoners and jail detainees [14]. These studies suggest 2 of the 
mechanisms by which drug use may impact VL, that is, receipt 
of and adherence to ART. While compelling, most studies have 
been cross-sectional and therefore unable to look at the lon-
gitudinal associations of abstinence with VL as examined in 
this study.
The more novel analyses are those that examine the impact 
of reducing drug use frequency without abstinence on VL. The 
impact of reducing frequency on VL has not been well studied, 
despite substance use interventions that focus on reducing fre-
quency even if abstinence is not achieved [18, 19]. Findings 
support the benefits of a harm reduction substance use treat-
ment model even when abstinence is not achieved [39–41]. We 
found that decreasing the frequency of illicit opioid and meth-
amphetamine/crystal use was associated with increased odds of 
VL suppression and significantly lower VL.
These results suggest that medication-assisted treatments 
to reduce opioid use may be beneficial for decreasing VL and 
improving outcomes, consistent with a recent meta-analysis 
[42]. These interventions may also have public health benefits 
since decreasing VL decreases HIV transmissibility to others. 
VL reduction associated with reducing methamphetamine/
crystal use highlights the importance of providing drug treat-
ment even if abstinence is not achieved. The VL improvement 
associated with changing from use of multiple drugs to a single 
drug also highlights the importance of intervening even if ab-
stinence is not achieved.
Study strengths include the large sample size; the longitu-
dinal approach, which allowed associations between change in 
drug use and VL to be examined rather than only cross-sec-
tional associations; and the ability to quantify drug use fre-
quency in order to examine not only current use vs abstinence 
Figure 1. Frequency of drug use at baseline among people living with human 
immunodeficiency virus who are current users of each drug.
Figure 2. Observed changes in frequency among people living with human immu-
nodeficiency virus who are current users of each drug at baseline.
but also reductions in use. Including multiple sites addressed 
a limitation of studies that lacked geographic diversity, a 
problem given known variations in drug use patterns across the 
United States [43]. The use of joint longitudinal and survival 
models allowed us to focus on viral suppression with repeated 
measures while also properly accounting for differential loss 
to follow-up. These models greatly improve the statistical esti-
mation for viral suppression, which is arguably the more clin-
ically meaningful endpoint. In addition, we examined VL as a 
continuous outcome, which provided more power and avoided 
Figure 4. The associations of decreasing or abstinence of 4 classes of drug use with relative viral load using fixed-effects meta-analysis to pool drug-specific estimates 
across studies. Abbreviation: CI, confidence interval.
Figure 3. The association of decreasing or abstinence of 4 classes of drug use with undetectable viral load. Abbreviation: CI, confidence interval.
the known limitations of dichotomizing continuous data [44], 
focusing on relative VL to avoid interpretation difficulties with 
log10VL. 
Limitations include the observational nature of the study. We 
focused on frequency rather than drug use disorder diagnoses. 
While reducing and stopping drug use was clearly associated 
with better VL, this does not necessarily indicate causality nor 
are all statistically significant changes in VL necessarily clini-
cally significant. Furthermore, we did not evaluate reasons 
why PLWH may have reduced frequency, such as medication-
assisted therapy for opioids and other types of interventions 
or mechanisms such as via adherence. We did not examine 
increased use separately; however, decreased use was the more 
clinically relevant goal. The large sample size from PLWH in 
care caused CNICS to dominate the pooled meta-analysis mod-
eled estimate when estimating the continuous relative VL out-
come. The heterogeneity of the population included in analyses 
examining relative VL may be a limitation; however, findings 
were similar in analyses limited to CNICS.
In future work, we will examine mediation analyses to better 
address such questions as how much of these impacts are being 
driven by adherence or other pathways. While benefits of 
medication-assisted therapy have been demonstrated for opioid 
use [42], studies that better address other drugs such as meth-
amphetamine or polydrug use would be beneficial.
In conclusion, we demonstrated associations over time with 
abstinence from illicit opioids, methamphetamines/crystal, 
cocaine/crack, and marijuana and viral suppression or lower 
VL. In addition, the impact on VL of reducing use of illicit 
opioid and methamphetamine/crystal without abstinence 
highlights the potential benefits of harm-reduction substance 
use interventions that are able to successfully reduce use even 
when abstinence is not achieved.
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